- Home
- WALD vs CAPR Comparison
WALD vs CAPR Comparison
Compare WALD & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- CAPR
- Stock Information
- Founded
- WALD 1988
- CAPR 2005
- Country
- WALD United States
- CAPR United States
- Employees
- WALD N/A
- CAPR N/A
- Industry
- WALD Package Goods/Cosmetics
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WALD Consumer Discretionary
- CAPR Health Care
- Exchange
- WALD Nasdaq
- CAPR Nasdaq
- Market Cap
- WALD 306.3M
- CAPR 324.6M
- IPO Year
- WALD 2021
- CAPR N/A
- Fundamental
- Price
- WALD $1.56
- CAPR $6.28
- Analyst Decision
- WALD Strong Buy
- CAPR Strong Buy
- Analyst Count
- WALD 5
- CAPR 8
- Target Price
- WALD $4.96
- CAPR $24.75
- AVG Volume (30 Days)
- WALD 528.0K
- CAPR 1.4M
- Earning Date
- WALD 11-11-2025
- CAPR 08-11-2025
- Dividend Yield
- WALD N/A
- CAPR N/A
- EPS Growth
- WALD N/A
- CAPR N/A
- EPS
- WALD N/A
- CAPR N/A
- Revenue
- WALD $273,868,000.00
- CAPR $13,392,150.00
- Revenue This Year
- WALD $10.37
- CAPR N/A
- Revenue Next Year
- WALD $14.37
- CAPR $6,061.53
- P/E Ratio
- WALD N/A
- CAPR N/A
- Revenue Growth
- WALD 25.55
- CAPR N/A
- 52 Week Low
- WALD $1.50
- CAPR $3.98
- 52 Week High
- WALD $4.40
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- WALD 35.98
- CAPR 36.33
- Support Level
- WALD $1.50
- CAPR $6.17
- Resistance Level
- WALD $1.79
- CAPR $7.30
- Average True Range (ATR)
- WALD 0.16
- CAPR 0.43
- MACD
- WALD 0.00
- CAPR -0.11
- Stochastic Oscillator
- WALD 10.00
- CAPR 4.53
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.